NovAliX and Servier Collaborate in Early Discovery Research Program
News Oct 10, 2012
NovAliX has announced that it has entered into drug discovery collaboration with the pharmaceutical company Servier.
NovAliX will identify hits using its Graffinity fragment-based screening technology that combines chemical micro-arrays with a proprietary SPR-imaging method for the detection of compound protein interactions.
NovAliX will receive technology access fees and research funding from Servier.
"We look forward to utilizing NovAliX's strong capabilities in biophysics and lead generation methodologies for this novel discovery program" said Bernard Marchand, PhD, Head of Servier Discovery Research.
Stephan Jenn, President of NovAliX, said "This drug discovery collaboration with a leading global pharmaceutical confirms the quality of our technologies and science, and underlines the value of our platform as an important tool to deliver valuable lead candidates."
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019